Search
BIOAGE Labs Inc
BIOAAdd to Watchlist
24.603USD
+0.343+1.41%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.09BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.41%
5 Days
+7.77%
1 Month
+43.04%
6 Months
+85.96%
Year to Date
+85.96%
1 Year
+495.71%
Key Figures
24.430Open
25.060High
261.68KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
24.260Prev. Close
24.110Low
4.78MTurnover
LossP/E Static
2.88P/B
0.00%Div Yield TTM
-24.26%ROA
24.00052wk High
0.36Volume Ratio
-71.11MNet Profit
44.39MShares
-2.4064EPS TTM
--Beta
-25.98%ROE
3.88052wk Low
3.92%Amplitude
100.00%Gross Margin
1.09BMarket Cap
10.45Reward/Risk
4.47%Risk Rate
TradingKey Stock Score of BIOAGE Labs Inc
Currency: USD Updated: 2026-07-01Key Insights
BIOAGE Labs Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.88.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BIOAGE Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BIOAGE Labs Inc Highlights
StrengthsRisks
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.99M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.99M.
Undervalued
The company’s latest PE is -10.08, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.69M shares, decreasing 9.72% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 193.51K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
42.875
Target Price
+74.93%
Upside Space
BIOAGE Labs Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BIOAGE Labs Inc Info
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
Ticker SymbolBIOA
CompanyBIOAGE Labs Inc
CEOFortney (Kristen)
Websitehttps://bioagelabs.com
Related Instruments
+1.33%
+2.83%
+5.32%
+3.44%
+2.26%
+3.06%
+3.01%
+2.95%
+3.47%
+1.82%
+4.20%
+1.56%
+3.97%
+3.16%
+2.05%
0.00%
+3.30%
+3.10%
+0.25%
+4.50%Popular Instruments
52754.900
+500.600 (+0.96%)
29261.900
-537.400 (-1.80%)
7464.800
-10.700 (-0.14%)
14764.000
-591.000 (-3.85%)
67914.000
-1571.000 (-2.26%)
6350.300
+74.900 (+1.19%)
68.364
+0.396 (+0.58%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4117.170
+86.400 (+2.14%)
FAQs
What is the current price of BIOAGE Labs Inc (BIOA)?
The current price of BIOAGE Labs Inc (BIOA) is 24.26.
What is the symbol of BIOAGE Labs Inc?
The ticker symbol of BIOAGE Labs Inc is BIOA.
What is the 52-week high of BIOAGE Labs Inc?
The 52-week high of BIOAGE Labs Inc is 24.00.
What is the 52-week low of BIOAGE Labs Inc?
The 52-week low of BIOAGE Labs Inc is 3.88.
What is the market capitalization of BIOAGE Labs Inc?
The market capitalization of BIOAGE Labs Inc is 1.08B.
Is BIOAGE Labs Inc (BIOA) currently rated as Buy, Hold, or Sell?
According to analysts, BIOAGE Labs Inc (BIOA) has an overall rating of Buy, with a price target of 42.88.
What is the Earnings Per Share (EPS TTM) of BIOAGE Labs Inc (BIOA)?
The Earnings Per Share (EPS TTM) of BIOAGE Labs Inc (BIOA) is -2.24.